Drug Information Association Logo
« Back to Listing

Protocol Deviations: Finding the Yellow Brick Road (Part 2 of 2)

Innovative Approaches to Ensuring Quality in Clinical Trials and Compliance to Good Clinical Practice

Day & Time:
June 16, 11:00AM - 12:30PM (Pacific Standard Time)

Session Number:

Room Number:



Protocol Deviations: Finding the Yellow Brick Road (Part 2 of 2)

Yvonne P. McCracken
Vice President, Clinical Operations and Compliance
Rx Trials Inc, United States

This two-part workshop addresses the lack of consistent terminology and methodology for managing and reporting protocol deviations. A hands-on experience will focus on developing a protocol deviation handling plan and classification of protocol deviations.

In Part 2, attendees will participate in a hands-on experience where a protocol deviation handling plan will be developed, potential protocol deviations will be prospectively identified and classified, and important protocol deviations will be identified for regulatory agency reporting. Tools will be provided to workshop attendees.

Preregistration is strongly recommended, and attendees are expected to attend both Part 1 and Part 2.

Part 1 will take place on Monday at 8:30 AM (Session #114).

Workshop sessions will be interactive so attendees are asked to download all handouts to tablet or laptop and bring to both workshop sessions. To secure a seat for this specific workshop, please email annualmeetingprogram@diahome.org, Subject line: Protocol Deviations Workshop.

**Due to workshop format, seating will be limited and will be available on a first come, first served basis.

The San Diego Convention Center has stringent regulations on maximum room capacities, and they are strictly enforced. Once all seats are occupied, DIA will be required to close the workshop, and no more participants will be admitted. Interested attendees are encouraged to arrive at workshops early in order to ensure seating. Please note, as a workshop with interactivity, this offering will not be recorded.

Learning Objective(s):
Develop a protocol deviation handling plan; Identify protocol deviations for reporting.

Presentation(s) & Speaker(s):
Maryrose Petrizzo, MSc
Senior Consultant
Halloran Consulting Group, Inc., United States

Munish Mehra, PhD
Executive Director, Business Development
Quantum Biopharma, United States